within Pharmacolibrary.Drugs.ATC.A;

model A07EC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.341 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008033333333333333,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Sulfasalazine is an anti-inflammatory and immunomodulatory drug composed of sulfapyridine and 5-aminosalicylic acid linked by an azo bond. It is primarily used for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and also for rheumatoid arthritis. Sulfasalazine is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Song, YK, et al., &amp; Maeng, HJ (2020). Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. <i>Pharmaceutics</i> 12(5) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics12050397&quot;>10.3390/pharmaceutics12050397</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32357395/&quot;>https://pubmed.ncbi.nlm.nih.gov/32357395</a></p></li><li><p>Wu, C, et al., &amp; Lu, D (2023). Regulation of BCRP expression and sulfasalazine pharmacokinetics by the nuclear receptor REV-ERBα. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 53(3) 215–222. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2023.2200839&quot;>10.1080/00498254.2023.2200839</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37039301/&quot;>https://pubmed.ncbi.nlm.nih.gov/37039301</a></p></li><li><p>Awni, WM, et al., &amp; Granneman, GR (1995). The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. <i>Clinical pharmacokinetics</i> 29 Suppl 2 98–104. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199500292-00014&quot;>10.2165/00003088-199500292-00014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8620678/&quot;>https://pubmed.ncbi.nlm.nih.gov/8620678</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07EC01;
